tbuckley/cabot-search huggingface dataset:
Hymenoptera-venom allergy, outcomes of immunotherapy and peripheral blood mast cell biomarkers in a non-European Mediterranean cohort
Authors: Alon Y. Hershko, Noa Shaharabani, Yossi Rosman, Keren Meir-Shafrir, Idit Lachover-Roth, Anat Cohen-Engler, Yoseph A. Mekori, Ronit Confino-Cohen
Journal: Journal of Allergy and Clinical Immunology (2019)

Most of the data on Hymenoptera venom allergy (HVA) is derived from European studies. We hypothesize that investigation of patients from a different geographic or ethnic origin may provide additional insights into HVA and its management. We included all patients who were referred for HVA immunotherapy in a single referral center (Meir Hospital, Israel). Patients were evaluated for baseline serum tryptase and peripheral-blood c-Kit D816V mutation. Clinical data were obtained from patient medical charts. A total of 153 subjects were enrolled, showing a low median age of 21 yrs, compared to 40-50 yrs in other studies. The most prevalent allergen was bee venom (89%, vs. 20-30% in European reports). Elevated tryptase levels were detected in only 5 subjects (3.3% vs. 10-16% as previously published) and c-Kit D816V mutation was found in 4 individuals (4.4%). Factors associated with severe sting anaphylaxis were advanced age, multiple venom sensitization and tryptase levels. Unlike other studies, the peak incidence of near-fatal reactions to stings was at tryptase values of 5.5-7.0 ng/mL rather than at higher levels. Similar to previous reports, bee venom sensitization was linked to VIT adverse reactions, however, with no correlation to tryptase levels. This Mediterranean cohort exhibits variations from previously published European studies on HVA patients. Our work underscores population differences suggesting that interpretation of risk factors should be adjusted to specific cohorts.
Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma
Authors: Laura D. Gamble, Stefania Purgato, Jayne Murray, Lin Xiao, Denise M. T. Yu, Kimberley M. Hanssen, Federico M. Giorgi, Daniel R. Carter, Andrew J. Gifford, Emanuele Valli, Giorgio Milazzo, Alvin Kamili, Chelsea Mayoh, Bing Liu, Georgina Eden, Sara Sarraf, Sophie Allan, Simone Di Giacomo, Claudia L. Flemming, Amanda J. Russell, Belamy B. Cheung, Andre Oberthuer, Wendy B. London, Matthias Fischer, Toby N. Trahair, Jamie I. Fletcher, Glenn M. Marshall, David S. Ziegler, Michael D. Hogarty, Mark R. Burns, Giovanni Perini, Murray D. Norris, Michelle Haber
Journal: Science Translational Medicine (2019)

MYCN regulates polyamines in neuroblastoma, and combined inhibition of polyamine synthesis and transport has therapeutic effects in mouse models.
Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT
Authors: Gary A. Ulaner, Lisa Bodei
Journal: Clinical Nuclear Medicine (2019)

Ga-DOTATATE is a radiolabeled somatostatin analog used for the detection and characterization of somatostatin receptor (SSR)-overexpressing tumors, particularly well-differentiated neuroendocrine tumors. We present a case of a 65-year-old man with well-differentiated pancreatic neuroendocrine tumor post-Whipple surgery and a new liver lesion on CT. Ga-DOTATATE PET/CT was performed for SSR characterization and restaging, which demonstrated the lesion to be intensely SSR positive and interpreted as a neuroendocrine metastasis. However, subsequent pathology proved the lesion to be a hepatocellular carcinoma. This case adds hepatocellular carcinoma as a potentially DOTATATE-avid malignancy to be considered in the differential diagnoses of SSR-positive liver lesions.
Markers of Esophageal Epithelial-Mesenchymal Transition Are Significantly Reduced in Active Eosinophilic Esophagitis Following 16 Weeks of Treatment With RPC4046, an Anti-Interleukin-13 Monoclonal Antibody
Authors: Peter Gann, Ryan Deaton, Nathan McMahon, Margaret H. Collins, Evan S. Dellon, Ikuo Hirano, Michael Grimm, Amy Woo, Mahinda Karunaratne, Allan Olson, Richard Aranda, Gregory J. Opiteck
Journal: Journal of Allergy and Clinical Immunology (2019)
Venetoclax Improves Quality of Life for Patients with Elapsed/Refractory Chronic Lymphocytic Leukemia
Authors: Tara Cochrane, Tatiana Chagorova, Tadeusz Robak, Su-Peng Yeh, Evgeny Nikitin, Madlaina Breuleux, Abdullah Masud, Kavita Sail, Viktor Komlosi, Mary Ann Anderson
Journal: Blood (2018)
Countries must do more to help migrants access healthcare, says WHO
Authors: Sophie Arie
Journal: BMJ (2019)

European countries must stop seeing migrants as a potential public health threat and must do more to help this vulnerable group to stay healthy in the countries they travel through and settle in, the World Health Organization has said.

In its first report on the health of refugees and economic migrants in the European region,1 WHO found very little evidence that this group spreads infectious diseases or places a disproportionate burden on healthcare systems. But it found that the …
Abstract 16884: Sudden Coronary Death in the Young: Evidence of a Contractile Phenotype of Smooth Muscle Cells in the Culprit Atherosclerotic Plaque
Authors: Stefania Rizzo, Matteo Coen, Antonija Sakic, Gaetano Thiene, Giulio Gabbiani, Cristina Basso, Marie-Luce Bochaton-Piallat
Journal: Circulation (2016)

Introduction: Atherosclerotic coronary artery disease precipitating sudden cardiac death (SCD) in the young is peculiar in terms of extent (single vessel), site (left anterior descending branch) and morphology (mostly fibrocellular due to smooth muscle cells [SMC] proliferation, in the absence of thrombosis) of the culprit atherosclerotic plaque (AP). Hypothesis: To characterize the SMCs phenotype in coronary AP from young SCD victims. Methods: Among 652 young ( 75% luminal area) and no thrombosis were selected for the study (all males, age range 17-40 years old, mean 33). AP from older (>40 years old) atherosclerotic SCD victims (n=8, 7 males) and normal coronary segments from young people (n=5, 4 males) were used for comparison. Besides traditional staining, the expression of α-smooth muscle actin (α-SMA), S100A4, smooth...
Regulation of Mitophagy By O-Linked N-Acetylglucosamine Transferase Is Essential for Hematopoietic Stem Cell Maintenance
Authors: Koichi Murakami, Daisuke Kurotaki, Wataru Kawase, Shunsuke Soma, Yumi Fukuchi, Hiroyoshi Kunimoto, Ryusuke Yoshimi, Shuhei Koide, Motohiko Oshima, Takako Hishiki, Noriyo Hayakawa, Tomomi Matsuura, Minoru Ko, Mayumi Oda, Kiichi Yanagisawa, Hiroshi Kobayashi, Yoshitoshi Atobe, Kengo Funakoshi, Atsushi Iwama, Keiyo Takubo, Shinichiro Okamoto, Tomohiko Tamura, Hideaki Nakajima
Journal: Blood (2018)
Abstract 13573: Baseline TG/HDL Predicts Future Type 2 Diabetes in a 12-year Follow up of Mexican Americans in Starr County, TX: 2002-2014
Authors: Xiaotao Zhang, Craig L Hanis, William B Perkison
Journal: Circulation (2017)

Introduction: The ratio of plasma triglycerides (TG) to HDL_cholesterol (HDL) was introduced as a tool to identify apparently healthy individuals at increased cardio-metabolic and diabetes risk. Th...
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Authors: Tina Gruosso, Mathieu Gigoux, Venkata Satya Kumar Manem, Nicholas Bertos, Dongmei Zuo, Irina Perlitch, Sadiq Mehdi Ismail Saleh, Hong Zhao, Margarita Souleimanova, Radia Marie Johnson, Anne Monette, Valentina Muñoz Ramos, Michael Trevor Hallett, John Stagg, Réjean Lapointe, Atilla Omeroglu, Sarkis Meterissian, Laurence Buisseret, Gert Van den Eyden, Roberto Salgado, Marie-Christine Guiot, Benjamin Haibe-Kains, Morag Park
Journal: Journal of Clinical Investigation (2019)

Understanding the tumor immune microenvironment (TIME) promises to be key for optimal cancer therapy, especially in triple-negative breast cancer (TNBC). Integrating spatial resolution of immune cells with laser capture microdissection gene expression profiles, we defined distinct TIME stratification in TNBC, with implications for current therapies including immune checkpoint blockade. TNBCs with an immunoreactive microenvironment exhibited tumoral infiltration of granzyme B+CD8+ T cells (GzmB+CD8+ T cells), a type 1 IFN signature, and elevated expression of multiple immune inhibitory molecules including indoleamine 2,3-dioxygenase (IDO) and programmed cell death ligand 1 (PD-L1), and resulted in good outcomes. An "immune-cold" microenvironment with an absence of tumoral CD8+ T cells was defined by elevated expression of the immunosuppressive marker B7-H4, signatures of fibrotic stroma, and poor outcomes. A distinct poor-outcome immunomodulatory microenvironment, hitherto poorly characterized, exhibited stromal restriction of CD8+ T cells, stromal expression of PD-L1, and enrichment for signatures of cholesterol biosynthesis. Metasignatures defining these TIME subtypes allowed us to stratify TNBCs, predict outcomes, and identify potential therapeutic targets for TNBC.
Abstract 12406: A Comparison of the Predictive Ability of Cardiovascular Biomarkers for the Incidence of Ischemic Stroke Subtypes in the General Population: B-type Natriuretic Peptide, C-reactive Protein, and Urinary Albumin Levels
Authors: Tomohiro Takahashi, Fumitaka Tanaka, Yasuhiro Ishibashi, Shinichi Omama, Toshiyuki Onoda, Kozo Tanno, Masaki Ohsawa, Kiyomi Sakata, Makoto Koshiyama, Kuniaki Ogasawara, Akira Okayama, Motoyuki Nakamura
Journal: Circulation (2017)

Background: B-type natriuretic peptide (BNP), high sensitive CRP, and urinary albumin corrected by urinary creatinine (UACR) have been suggested to be useful predictors for the development of strok...
Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma.
Authors: Nicola Personeni, Tiziana Pressiani, Antonio D'Alessio, Maria Giuseppina Prete, Silvia Bozzarelli, Valeria Smiroldo, Matteo Simonelli, Laura Giordano, Armando Santoro, Lorenza Rimassa
Journal: Journal of Clinical Oncology (2019)

406 Background: Prognostic factors of survival and disease course in patients with hepatocellular carcinoma (HCC) and preserved liver reserves, enrolled onto clinical trials of second-line treatments after sorafenib, are unclear. Methods: This single-center database analysis included all patients with Child-Pugh A score and ECOG performance status (PS) 0 - 1 participating between 2012 and 2017 in clinical trials of second-line systemic treatments for advanced HCC. Patients received first-line sorafenib and experienced either disease progression (PD) to sorafenib or were sorafenib-intolerant. Their clinicopathologic characteristics were correlated with overall survival (OS, calculated from the first day of second-line treatment to death or last visit available), and post-treatment survival (PTS, calculated from the date of end-of-treatment to death or last follow-up). Results: Ninety-nine patients (21 sorafenib-intolerant, 78 progressors) were enrolled onto trials of checkpoint inhibitors (CPI, 23 patients), tyrosine kinase inhibitors (TKI, 44 patients) versus best supportive care (BSC, 24 patients), open-label TKI (8 patients). Overall, median OS was 9.4 months (9.6, 9.8, and 8.0 months for CPI, TKI and BSC, respectively; p = 0.493). Median time-to-treatment failure was 3.5, 4.4, 3.7 months for CPI, TKI and BSC, respectively (p = 0.561). In multivariable analyses, worse OS was linked to high neutrophil/lymphocyte ratio (Hazard Ratio, HR = 1.13; p = 0.005) and macrovascular invasion [(MVI), HR = 2.59; p &lt; 0.001]. Second-line treatment discontinuation due to liver failure independently conferred worse PTS than adverse events (HR = 2.32; p = 0.111) or PD (HR = 3.44; p = 0.002), as did ECOG PS &gt; 1 at EOT (HR = 3.05; p = 0.002). Death rate within 30 days of end-of-treatment was 4.2% on placebo versus 10.5% on IO versus 22.9% on TKI. Conclusions: In this homogeneous cohort of compensated HCC patients pre-treated with sorafenib, MVI and NLR at start of second-line clinical trial are prognostic factors of OS. Besides ECOG PS and liver failure, further predictors of subsequent PTS to inform treatment options beyond second-line were not identified.
Abstract 17243: Seasonal Variation of Ventricular Tachycardia and Ventricular Fibrillation
Authors: Mohit Pahuja, Ronak G Soni, Neeraj Shah, Nirmanmoh Bhatia, Sahil Agrawal, Aman Handa, Dhara Patel, Sana A Kamdar, Nasir Hussain, Ananthram Kalya
Journal: Circulation (2016)

Background: Ventricular tachycardia (VT) and Ventricular fibrillation (VF) are the most common causes of sudden cardiac death in the US, with approximately 300, 000 deaths per year. Studies have sh...
Detection of Clinically Relevant Molecular Alterations in Chronic Lymphocytic Leukemia (CLL) By Nanopore Sequencing
Authors: Adam Burns, David Robert Bruce, Pauline Robbe, Adele Timbs, Basile Stamatopoulos, Ruth Clifford, Maria Lopopolo, Duncan Parkes, Kate E Ridout, Anna Schuh
Journal: Blood (2018)
TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors
Authors: Yuki Nishida, Jo Ishizawa, Vivian Ruvolo, Michael Andreeff
Journal: Blood (2018)
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
Authors: Omar Mamlouk, Umut Selamet, Shana Machado, Maen Abdelrahim, William F. Glass, Amanda Tchakarov, Lillian Gaber, Amit Lahoti, Biruh Workeneh, Sheldon Chen, Jamie Lin, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Nizar Tannir, Cassian Yee, Adi Diab, Ala Abudayyeh
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Rationale &amp; Objective</h3> The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of these agents. The literature on the nephrotoxicity of CPI is limited. Here, we present cases of biopsy proven acute tubulointerstitial nephritis (ATIN) and glomerulonephritis (GN) induced by CPIs and discuss potential mechanisms of these adverse effects. <h3>Study design, setting, &amp; participants</h3> We retrospectively reviewed all cancer patients from 2008 to 2018 who were treated with a CPI and subsequently underwent a kidney biopsy at The University of Texas MD Anderson Cancer Center. <h3>Results</h3> We identified 16 cases diagnosed with advanced solid or hematologic malignancy; 12 patients were male, and the median age was 64 (range 38 to 77 years). The median time to developing acute kidney injury (AKI) from starting CPIs was 14 weeks (range 6–56 weeks). The average time from AKI diagnosis to obtaining renal biopsy was 16 days (range from 1 to 46 days). Fifteen cases occurred post anti-PD-1based therapy. ATIN was the most common pathologic finding on biopsy (14 of 16) and presented in almost all cases as either the major microscopic finding or as a mild form of interstitial inflammation in association with other glomerular pathologies (pauci-immune glomerulonephritis, membranous glomerulonephritis, C3 glomerulonephritis, immunoglobulin A (IgA) nephropathy, or amyloid A (AA) amyloidosis). CPIs were discontinued in 15 out of 16 cases. Steroids and further immunosuppression were used in most cases as indicated for treatment of ATIN and glomerulonephritis (14 of 16), with the majority achieving complete to partial renal recovery. <h3>Conclusions</h3> Our data demonstrate that CPI related AKI occurs relatively late after CPI therapy. Our biopsy data demonstrate that ATIN is the most common pathological finding; however it can frequently co-occur with other glomerular pathologies, which may require immune suppressive therapy beyond corticosteroids. In the lack of predictive blood or urine biomarker, we recommend obtaining kidney biopsy for CPI related AKI.
Abstract 15366: Comparative Effectiveness and Safety Between Reduced Dose Dabigatran, Reduced Dose Rivaroxaban and Warfarin Among Oldest Old Atrial Fibrillation Patients
Authors: Chao-Lun Lai, Ho-Min Chen, Min-Tsun Liao, Ting-Tse Lin
Journal: Circulation (2017)

Introduction: Previous studies have shown that both dabigatran and rivaroxaban were associated with better clinical outcomes compared with warfarin in elderly atrial fibrillation (AF) patients. Red...
Comparison of adjuvant chemotherapy, chemoradiation, and chemotherapy followed by chemoradiation for resected stage I-II pancreatic cancer.
Authors: Sung Jun Ma, Gregory Hermann, Kavitha M Prezzano, Lucas M Serra, Austin J Iovoli, Anurag K Singh
Journal: Journal of Clinical Oncology (2019)

372 Background: Prior National Cancer Database (NCDB) studies have demonstrated an overall survival (OS) benefit for adjuvant concurrent chemoradiation (CRT) compared to chemotherapy alone. Given the more recent adoption of postoperative chemotherapy followed by concurrent chemoradiation (C+CRT), this NCDB analysis evaluates the clinical outcomes of C+CRT compared to CRT alone or adjuvant chemotherapy alone (C) for resected pancreatic cancer. Methods: The NCDB was queried for primary stage I-II, cT1-3N0-1M0, resected pancreatic adenocarcinoma treated with adjuvant C, CRT, or C+CRT (2004-2015). Patients treated with C+CRT were compared with those treated with C (cohort C) or with CRT (cohort CRT). The primary endpoint was overall survival (OS). Baseline patient, tumor, and treatment characteristics were examined. Kaplan-Meier analysis, multivariable Cox proportional hazards method, forest plot, and propensity score matching were used. Results: Among 5667 patients (n = 3031 for C, n = 1307 for CRT, n = 1329 for C+CRT), median follow-up was 34.7 months, 45.2 months, and 39.7 months for the C, CRT, and C+CRT cohorts, respectively. In the multivariable analysis for all patients, C (HR 1.31, p &lt; 0.001) and CRT (HR 1.24, p &lt; 0.001) were associated with worse mortality compared to C+CRT. Treatment interactions were seen among pathologically node positive disease. C+CRT was favored in 1-3 (HR 0.74, p &lt; 0.001) and 4+ (HR 0.75, p &lt; 0.001) positive lymph node disease when compared to C or CRT alone, but none of the treatment options were significantly favored in node negative disease (HR 0.96, p = 0.67). Using 1:1 propensity score matching, 2152 patients for cohort C and 1774 patients for cohort CRT were matched. C+CRT remained significant for improved OS for both cohort C (median OS 23.3 vs 20.0 months, p &lt; 0.001) and cohort CRT (median OS 23.4 vs 20.8 months, p &lt; 0.001). Conclusions: This NCDB study using propensity score matched analysis demonstrates an OS benefit for C+CRT compared to C or CRT alone following surgical resection of pancreatic cancer. Most of this benefit is in patients with positive lymph nodes.
Gastrostomy tube for nutrition and bowel obstruction in patients with advanced malignancy: Less is more.
Authors: Gabrielle Gauvin, Chi Chi Do-Nguyen, Leigh T Selesner, Eileen O'Halloran, Johanna Lou, Molly Collins, Jeffrey M. Farma
Journal: Journal of Clinical Oncology (2019)

700 Background: Malnutrition and malignant bowel obstruction (MBO) are common consequences of advanced malignancy. Both lead to a poor prognosis, frequent hospitalizations, and have a negative impact on quality of life. The aim of this study is to explore gastrostomy tube (g-tube) placement practices to better define the role of g-tube role in advanced malignancy. Methods: Patients who underwent g-tube placement at our tertiary cancer care center between 2013 and 2017 were included in this study. Patients’ demographics, diagnosis, procedures, postoperative course, and clinical data were collected. Complications and survival were used as endpoints. Results: Two hundred forty-two cancer patients with an average age at diagnosis of 61 years (range 21-94) underwent g-tube placement for nutrition (76.4%), decompression (MBO) (22.7%), or both (0.8%). Active treatment within 3 months of g-tube insertion was seen in 37.8% of the nutrition group versus 29.1% in the MBO group (p = 0.208). Successful insertion was achieved in 96.8% of patients, but nine patients required more than one method of insertion attempt. In the nutrition group, successful method of insertion was 88.1% in interventional radiology, 8.1% in operating room, and 3.8% in endoscopy suite, compared to 81.8%, 14.5%, and 3.6% for the MBO group, respectively (p = 0.426). Post-placement complications were significantly less common in the MBO group compared to the nutrition group (24.1 vs. 54.3%, p &lt; 0.001). Consultation pattern in the MBO group revealed that 45.5% had a palliative care consult, 56.4% were seen by social work, and 47.3% went to hospice. Survival in the MBO group was significantly shorter than in the nutrition group at 30 days (52.7 vs. 90.3%, p &lt; 0.001), 1-year (54.6 vs. 5.9%, p&lt;0.001), and three years (24.1 vs 1.8%, p = 0.001) after g-tube placement. Conclusions: In our experience, most patients who undergo g-tube insertion are not receiving active treatment and a large proportion of patients who receive a decompressive g-tube have a life expectancy of less than a month. These findings will inform the next step of our study: creating a discussion tool to coordinate better care and interventional decision making for patients with advanced malignancy.
Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis
Authors: Lisa Zhou, Alexandra Leonard, Ana B. Pavel, Kunal Malik, Aishwarya Raja, Jacob Glickman, Yeriel D. Estrada, Xiangyu Peng, Ester del Duca, Juan Sanz-Cabanillas, Juan Ruano, Hui Xu, Ning Zhang, Huei-Chi Wen, Juana Gonzalez, Sandra Garcet, James G. Krueger, Emma Guttman-Yassky
Journal: Journal of Allergy and Clinical Immunology (2019)
Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia
Authors: Michael Byrne, Mark G. Frattini, Oliver G. Ottmann, Ioannis Mantzaris, Martin Wermke, Daniel J. Lee, Daniel Morillo, Arne Scholz, Stuart Ince, Ray Valencia, Fabricio Souza, Raul Cordoba
Journal: Blood (2018)
The impact of the new Global Lung Function Initiative <i>T</i><sub>LCO</sub> reference values on trial inclusion for patients with idiopathic pulmonary fibrosis
Authors: Monique Wapenaar, Jelle R. Miedema, Catharina J. Lammering, Frans W. Mertens, Marlies S. Wijsenbeek
Journal: European Respiratory Journal (2019)

<b>Adopting the new Global Lung Function Initiative <i>T</i></b><sub><b>LCO</b></sub><b>reference values may positively impact clinical trial eligibility for IPF patients</b>http://ow.ly/bOMn30n2YOP
Changes in Whole Blood Transcriptome during Peanut-Induced Anaphylaxis and Correlation with Symptoms
Authors: Paul J. Turner, Nandinee Patel, Monica Ruiz-Garcia, Isabel J. Skypala, Stephen R. Durham, Robert J. Boyle, Kathleen Y. Wang, Shuopeng Wu, Hongzhe Li, Jonathan M. Spergel
Journal: Journal of Allergy and Clinical Immunology (2019)
Increased Recruitment and Retention of Pediatric Research Participants after Implementation of Novel Recruitment Strategies in Inner City Asthma Consortium Site.
Authors: Anna-Liisa B. Vockell, Kristi Curtsinger, Pamela Groh, Carolyn Kercsmar, Gurjit K. Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2019)
Proteome Analyses and Single-Cell RNA Sequencing Reveal Age-Dependent Re-Wiring of Central Carbon Metabolism in Myeloid-Biased Subsets of Human Hematopoietic Stem Cells
Authors: Marco L Hennrich, Natalie Romanov, Patrick Horn, Samira Jaeger, Volker Eckstein, Laura Poisa-Beiro, Jacqueline Boultwood, Thomas Luft, Andrea Pellagatti, Peer Bork, Patrick Aloy, Anne-Claude Gavin, Anthony D. Ho
Journal: Blood (2018)